Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of DirectorsGlobeNewsWire • 03/12/24
Atossa Therapeutics to present data from ongoing Phase 2 breast cancer trialProactive Investors • 03/06/24
Atossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trialProactive Investors • 02/22/24
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS StudyGlobeNewsWire • 02/22/24
Atossa Therapeutics' ‘standalone and superior drug' Z-endoxifen for breast cancer seen boosting shares by 300%Proactive Investors • 02/12/24
Atossa Therapeutics achieves patient enrollment milestone for Phase 2 breast cancer trialProactive Investors • 02/07/24
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical TrialGlobeNewsWire • 02/07/24
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the MarketInvestorPlace • 01/16/24
Atossa Therapeutics CEO dialogue between doctors and patients about breast density in 2024Proactive Investors • 01/09/24
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical DirectorGlobeNewsWire • 12/04/23
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical TrialGlobeNewsWire • 11/20/23
Atossa Therapeutics advances (Z)-endoxifen for breast cancer research program during 3QProactive Investors • 11/13/23
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/23
Atossa Therapeutics adds experienced finance exec to board of directorsProactive Investors • 11/09/23
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of DirectorsGlobeNewsWire • 11/09/23
Atossa Therapeutics' (Z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situProactive Investors • 10/30/23
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini GroupPRNewsWire • 10/30/23
Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades laterPRNewsWire • 10/11/23
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And TreatmentAccesswire • 09/18/23
Atossa Therapeutics' upcoming breast cancer trial results expected to drive stock higherProactive Investors • 09/08/23
Atossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral EndoxifenProactive Investors • 08/23/23
Atossa Therapeutics has analysts bullish as it advances breast cancer therapeuticProactive Investors • 08/14/23